Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Gust, Deborah A ^a   Mosimaneotsile, Barudi ^b   Mathebula, Unami ^b   Chingapane, Balladiah ^b   Gaul, Zaneta ^a   Pals, Sherri L ^a   Samandari, Taraz ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID; PLACEBO; PYRIDOXINE;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BOTSWANA; CD4 LYMPHOCYTE COUNT; CLINICAL RESEARCH; CONTROLLED STUDY; DISTANCE FROM CLINIC; DRUG USE; EDUCATIONAL STATUS; EMPLOYMENT; FEMALE; FOLLOW UP; GENDER; HEALTH CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCOME; LOSS TO FOLLOW UP; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PHARMACEUTICAL CARE; PHARMACY REFILL; PREGNANCY; PUBLIC HEALTH CLINIC; RISK FACTOR; SELF REPORT; SOCIOECONOMICS; STIGMA; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; CASE CONTROL STUDY; CLINICAL TRIAL; HEALTH SURVEY; INTERVIEW; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; URINE;

ADULT; BOTSWANA; CASE-CONTROL STUDIES; FEMALE; HEALTH SURVEYS; HUMANS; INTERVIEWS AS TOPIC; ISONIAZID; LOST TO FOLLOW-UP; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; REGRESSION ANALYSIS; RISK FACTORS; SELF REPORT;

EID: 79955567839     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018435     Document Type: Article

References (32)

1. Samandari T, Agizew T, Nyirenda S, Tedla Z, Sibanda T, et al. (2011) 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV-infection in Botswana:a randomized, double-blind, placebo-controlled trial. Lancet in press.
2. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, et al. (1999) Isoniazid prophylaxis for tuberculosis in HIV infection:a meta-analysis of randomized controlled trials. AIDS 13: 501-7.
3. Osterberg L, Blaschke T, (2005) Adherence to medication. N Engl J Med 353: 487-97.
4. Ngamvithayapong J, Uthaivoravit W, Yanai H, Akarasewi P, Sawanpanyalert P, (1997) Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thailand. AIDS 11: 107-12.
5. Amico KR, Harman JJ, O'Grady MA, (2008) Attrition and related trends in scientific rigor:a score card for ART adherence intervention research and recommendations for future directions. Curr HIV/AIDS Rep 5: 172-85.
6. Menzies R, Rocher I, Vissandjee B, (1993) Factors associated with compliance in treatment of tuberculosis. Tuber Lung Dis 74: 32-7.
7. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, et al. (1998) Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 12: 2447-57.
8. Comstock GW, (1999) How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 3: 847-50.
9. Mosimaneotsile B, Mathoma A, Chengeta B, Nyirenda S, Agizew TB, et al. (2009) Isoniazid Tuberculosis Preventive Therapy in HIV-Infected Adults Accessing Antiretroviral Therapy:A Botswana Experience, 2004-2006. J Acquir Immune Defic Syndr 54: 71-7.
10. Greenberg RS, Daniels SR, Flanders WD, Eley JW, Boring JR, (1996) Medical Epidemiology, Norwalk CT Appleton & Lange 2nd edition.
11. Shadish WR, Cook TD, Campbell DT, (2002) Experimental and Quasi-Experimental Designs for generalized causal inference. Boston Houghton Mifflin.
12. Eidus L, Hamilton EJ, (1963) A new method for the determination of N-ACETYL Isoniazid in urine of ambulatory patients. Am Rev Respir Dis 89: 587-8.
13. Patton, MQ, (2002) Qualitative Research and Evaluation Methods. Thousand Oaks, CA Sage Publications. 3rd Edition.
14. Gao X, Nau DP, Rosenbluth SA, Scott V, Woodward C, (2000) The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care 12: 387-98.
15. Sung SK, Lee SG, Lee KS, Kim DS, Kim KH, et al. (2009) First-year treatment adherence among outpatients initiating antihypertensive medication in Korea: results of a retrospective claims review. Clin Ther 31: 1309-20.
16. Hawken MP, Meme HK, Elliott LC, Chakaya JM, Morris JS, et al. (1997) Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults:results of a randomized controlled trial. AIDS 11: 875-82.
17. Churchyard GJ, Fielding K, Charalambous S, Day JH, Corbett EL, et al. (2003) Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans:time to change policy? AIDS 17: 2063-70.
18. Pekovic V, Mayanja H, Vjecha M, Johnson J, Okwera A, et al. (1998) Comparison of three composite compliance indices in a trial of self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. J Clin Epidemiol 51: 597-607 Uganda-Case Western Reserve University Research Collaboration.
19. Toure S, Kouadio B, Seyler C, Traore M, Koury-Dogbo N, et al. (2008) Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 22: 873-82.
20. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, et al. (2006) Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 20: 41-8.
21. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, et al. (2006) Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 43: 78-84.
22. Chesney MA, (2000) Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 30 (Suppl 2): S171-S176.
23. Weiser SD, Leiter K, Heisler M, McFarland W, Percy-de KF, et al. (2006) A population-based study on alcohol and high-risk sexual behaviors in Botswana. PLoS Med 3: e392.
24. Stone VE, (2001) Strategies for optimizing adherence to highly active antiretroviral therapy:lessons from research and clinical practice. Clin Infect Dis 33: 865-72.
25. Kwara A, Herold JS, Machan JT, Carter EJ, (2008) Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest 133: 862-8.
26. Basch E, (2010) The missing voice of patients in drug-safety reporting. N Engl J Med pp. 865-9.
27. Kleeberger CA, Buechner J, Palella F, Detels R, Riddler S, (2004) Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS 18: 683-8.
28. Watson-Jones D, Baisley K, Rusizoka M, Tanton C, Mugeye K, et al. (2009) Measurement and predictors of adherence in a trial of HSV suppressive therapy in Tanzania. Contemp Clin Trials 30: 504-12.
29. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, et al. (2001) Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acqui Immune Defic Syndr. pp. 445-9.
30. Tornee S, Kaewkungwal J, Fungladda W, Silachamroon U, Akarasewi P, et al. (2005) Factors associated with the household contact screening adherence of tuberculosis patients. Southeast Asian J Trop Med Public Health 36: 331-40.
31. Eholié SP, Tanon A, Polneau S, Ouiminga M, Djadji A, et al. (2007) Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan,Côte d'Ivoire J Acquir Immune Defic Syndr. 45: 355-8.
32. Barnhoorn F, Adriaanse H, (1992) In search of factors responsible for noncompliance among tuberculosis patients in Wardha District, India. Soc Sci Med 34: 291-306.